LY 264826与万古霉素针对100株耐甲氧西林金黄色葡萄球菌临床分离株及100株艰难梭菌临床分离株的体外活性比较。
In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
作者信息
Fasola E L, Moody J A, Gerding D N, Peterson L R
机构信息
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55417.
出版信息
Antimicrob Agents Chemother. 1990 Oct;34(10):2007-8. doi: 10.1128/AAC.34.10.2007.
Abstract
The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).
摘要
将新型糖肽类抗生素LY 264826的体外活性与万古霉素针对100株耐甲氧西林金黄色葡萄球菌和艰难梭菌的活性进行了比较。按重量计算，LY 264826对所测试的分离菌株的活性高于万古霉素。LY 264826与人血清蛋白的结合率为15.3%（范围为9.8%至21.8%）。
相似文献
1
In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
Antimicrob Agents Chemother. 1990 Oct;34(10):2007-8. doi: 10.1128/AAC.34.10.2007.
2
Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52. doi: 10.1128/AAC.06257-11. Epub 2012 Mar 5.
3
Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
Bioorg Med Chem Lett. 2002 Nov 4;12(21):3027-31. doi: 10.1016/s0960-894x(02)00664-9.
4
Balhimycin, a new glycopeptide antibiotic produced by Amycolatopsis sp. Y-86,21022. Taxonomy, production, isolation and biological activity.
J Antibiot (Tokyo). 1994 Mar;47(3):334-41. doi: 10.7164/antibiotics.47.334.
5
Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
Infection. 1998 May-Jun;26(3):165-7. doi: 10.1007/BF02771843.
6
Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility.
J Clin Microbiol. 1999 Sep;37(9):3068-71. doi: 10.1128/JCM.37.9.3068-3071.1999.
7
In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 1991 Jan;35(1):195-7. doi: 10.1128/AAC.35.1.195.
8
Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.
Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.
9
In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis.
J Antimicrob Chemother. 2001 Jan;47(1):83-6. doi: 10.1093/jac/47.1.83.
10
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
引用本文的文献
1
In vitro activity of the new glycopeptide LY264826 versus vancomycin against clinical isolates of enterococci.
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):982-3. doi: 10.1007/BF02005460.
本文引用的文献
1
Assay of 27 antimicrobials using a microbiological method.
Minn Med. 1983 May;66(5):321-4.
2
Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics.
J Infect Dis. 1977 Dec;136(6):778-83. doi: 10.1093/infdis/136.6.778.
Zotero 插件